After their advanced kidney tumors were surgically removed, nine patients were protected from the cancer returning thanks to ...
The safety and short-term efficacy of neoadjuvant chemotherapy in elderly patients with resectable locally advanced esophageal squamous cell carcinoma. This is an ASCO Meeting Abstract from the 2025 ...
A single-center study suggests the surgery is safe and effective even when tumors are large or located in high-risk areas.
In resectable, locally advanced esophageal squamous cell carcinoma, neoadjuvant Tyvyt plus chemoradiotherapy led to an ...
The addition of sintilimab to neoadjuvant chemoradiotherapy achieved a 60% pathological complete response rate vs 47.3% with ...
The following is a summary of “Antibiotics use decreases survival in cutaneous squamous cell carcinoma patients receiving ...
Paclitaxel oral solution versus paclitaxel injection as a second-line therapy in advanced gastric cancer: A randomized, open-label, non-inferiority phase 3 trial. This is an ASCO Meeting Abstract from ...
A phase 3 trial is evaluating ASP-1929 photoimmunotherapy plus Keytruda in first-line treatment for recurrent head and neck ...
Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® ...
In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report), ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback